Gli Inibitori di Pompa Protonica Aggiornamento.pdf - Farmaci Abruzzo

Bibliografia
1) Gruppo OsMed. L’uso dei farmaci in Italia. Rapporto nazionale anno 2010. Roma: Il Pensiero
Scientifico Editore, 2011
2) Lanas A, Wu P, Medin J, Mills EJ. Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal
bleeding in a Meta-Analysis. Clin Gastroenterol Hepatol 2011: Jun 6.
3) Ubaldi E, Tosetti C “Gli inibitori di pompa protonica”. Prescivere, Rivista SIMG 2002; 4-5: 23-9.
4) Earnest DL, Dorsch E, Jones J, Iennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of
lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 3: 238-43.
5) Baldi F, Crotta S, Morelli A, et al. Linee Guida per la gestione dei pazienti con malattia da reflusso
gastro-esofageo. G Gastroenterol 2000; 5:78-82.
6) Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of
reflux disease management-the Genval workshop report. Gut 1999; 44 (Suppl.2):S1-16.
7) Bardhan KD, Müller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, et al. Symptomatic gastrooesophageal
reflux disease: double blind controlled study of intermittent treatment with omeprazole
or ranitidine. BMJ 1999; 318:502-7.
8) Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, et al. On demand therapy with
omeprazole for the long-term management of patients with heartburn without oesophagitis-a
placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
9) Hassan-Alin M. Eur J Clin Pharmacol. 2005.
10) Andersson T. Aliment Pharmacol Ther 2001
11) Clin Gastronterol Hepatol 2006
12) McDonagh MS. Drug Effectiveness Review Project, 2009
13) Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22:266-80;
14) FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with
the use of proton pump inhibitors (Internet) Maggio 2010 disponibile all’indirizzo:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/uc
m213206.htm
15) Yang Y.X et al. Long-term PPI therapy and risk of hip fracture. JAMA 2006; 296: 2947-53
16) Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton Pump Inhibitors and Risk of
Fracture: A Systematic Review and Meta-Analysis of Observational Studies. Am J Gastroenterol. 2011;
Apr 12.
17) Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J. Proton pump inhibitors therapy and risk of hip
fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011: Jun 22.
18) Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of
11 international studies. Am J Med. 2011;124:519-26.
Direzione Politiche della Salute-Servizio Assistenza Farmaceutica e Trasfusionale
Aggiornamento dicembre 2011
12